New hope for Hard-to-Treat leukemia? early trial combines three drugs

NCT ID NCT07511062

Not yet recruiting Disease control Sponsor: Northside Hospital, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how many patients achieve remission without detectable cancer cells. It will enroll 32 adults who have not been treated before or are in their first relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axatilimab combined with decitabine and venetoclax
What this could lead to: If successful, this could offer a new treatment option for people with a hard-to-treat form of acute myeloid leukemia (AML) that has a TP53 mutation.
What could go wrong: This is a very early (Phase 1) trial with only 32 participants, so the main goal is safety and dosing, not proof of effectiveness. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA TP53 GENE MUTATION

Contacts and locations

Locations

Northside Hospital, Inc.

Atlanta, Georgia, 30342, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.